Diffusion Pharmaceuticals (DFFN) Stock Price, News & Analysis

Company Overview

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.

Key Stats

• Today's Range: N/A
• 50-Day Range: $4.38 to $6.60
• 52-Week Range: N/A
• Volume: 351,000 shs
• Average Volume: 10,937 shs
• Market Capitalization: $8.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

DFFN Stock Analysis - Frequently Asked Questions

How were Diffusion Pharmaceuticals' earnings last quarter?

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($9.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.00) by $6.00.

When did Diffusion Pharmaceuticals' stock split?

Shares of Diffusion Pharmaceuticals reverse split before market open on Thursday, August 17th 2023. The 1-1.5 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 67 shares after the split.

What other stocks do shareholders of Diffusion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Diffusion Pharmaceuticals investors own include Tonix Pharmaceuticals (TNXP), Onconova Therapeutics (ONTX), OPKO Health (OPK), T2 Biosystems (TTOO), NightHawk Biosciences (NHWK), Sorrento Therapeutics (SRNE) and TherapeuticsMD (TXMD).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 5/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:DFFN
• CIK: 1053691
• Web: www.diffusionpharma.com
• Phone: (434) 220-0718
• Fax: 434-220-0722
• Employees: 13
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-15,590,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -69.96%
• Return on Assets: -62.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.71
• Quick Ratio: 10.71

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.97 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 2,040,000
• Free Float: 2,003,000
• Market Cap: $8.98 million
• Optionable: Not Optionable
• Beta: 1.78